awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36158391-68DC8465-6124-41F1-A188-49CC2B6AF8C6
Q36158391-68DC8465-6124-41F1-A188-49CC2B6AF8C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36158391-68DC8465-6124-41F1-A188-49CC2B6AF8C6
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
P2860
Q36158391-68DC8465-6124-41F1-A188-49CC2B6AF8C6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36158391-68DC8465-6124-41F1-A188-49CC2B6AF8C6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b8c8ae4b44ad631074897094ef7d19c45284173e
P2860
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a